Ignite Creation Date:
2024-05-06 @ 12:53 PM
Last Modification Date:
2024-10-26 @ 1:05 PM
Study NCT ID:
NCT03871348
Status:
TERMINATED
Last Update Posted:
2024-03-05
First Post:
2019-01-24
Brief Title:
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sponsor:
Sanofi
Organization:
Sanofi
Organization Data
Organization:
Sanofi
Class:
INDUSTRY
Study ID:
TED15297
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sanofi
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| BioNTech RNA Pharmaceuticals GmbH | INDUSTRY |